Skip to main content

Vectus Biosystems

Research & Development into Cardiovascular Fibrosis & Blood Pressure. Vectus Biosystems holds patents around the Vasoactive Intestinal Peptide and its fragments as a therapeutic candidate to treat cardiovascular fibrosis and systolic blood pressure
  • Details

Screen-Shot-2023-06-22-at-92451-am

Type
Business Organisation